ТЕРАПИЯ СИНДРОМА ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ У ЖЕНЩИН С НОРМАЛЬНОЙ МАССОЙ ТЕЛА
##article.subject##:
PCOS, hirsutizm, giperandrogenizm, anovulyatsiya##article.abstract##
Polikistik tuxumdon sindromi (PCOS) reproduktiv yoshdagi ayollarga ta'sir qiladigan keng tarqalgan endokrinopatiyadir. Umumiy belgilarga hayz ko'rish buzilishi, giperandrogenizm va polikistik tuxumdon morfologiyasi kiradi, ammo ko'rinishlar heterojen bo'lishi mumkin. Insulinga nisbatan kuzatilgan qarshilig gormonal va metabolik kasalliklarning sababi deb hisoblanadi. PCOS ikkita fenotipga ega: ortiqcha vazn / semizlik va oriq, oxirgi fenotip sindromning kamroq tarqalgan namoyonidir.
Ushbu sharhning maqsadi asosiy xususiyatlarni umumlashtirish va so'nggi adabiyotlar asosida PCOS bilan kam vaz deb tashxis qo'yish va davolash algoritmlarini ishlab chiqishdir.
Natijalar. Gormonal, metabolik va gematologik profillar PCOS bilan kasallangan kam vaznli ayollarda sog'lom ayollarga nisbatan o'zgartirildi. Biroq, buzilishlar PCOS bilan kasallangan semiz ayollarga nisbatan taqqoslanadigan yoki kamroq aniq edi. Insulin qarshiligi semirishdan qat'i nazar, PCOSGA xosdir. Davolash usullari orasida tana vaznini normal ushlab turish, metformin kabi insulin sezgichlari yordamida ovulyatsiyani tiklash, hirsutizm, husnbuzar va hayz ko'rish disfunktsiyasi kabi alomatlardan xalos bo'lish kiradi, bularning barchasi umidvor natijalarni ko'rsatdi.
Xulosa PCOS bilan oldingi tadqiqotlar natijalarini tasdiqlash va ushbu sharhda tavsiya etilgan diagnostika va davolash algoritmlarini birlashtirish uchun rejalashtirilgan randomizatsiyalangan nazorat ostida tadqiqotlar o'tkazish kerak. Ushbu hujjat tibbiyot mutaxassislariga PCOS bilan kasallangan kam vaznli ayollarni boshqarishda klinik yondashuvni yaxshilashga yordam beradi.
Библиографические ссылки
Abu Hashim H, Foda O, El Rakhawy M. Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2018;297:859–70.
Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315:215–9.
Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Arch Gynecol Obstet. 2017;296:363–71.
Arentz S, Abbott JA, Smith CA, Bensoussan A. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014;14:511.
Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2016;188:118–26.
Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S,Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian
Atiomo W, Sinha A. The role of metformin in the treatment of infertile women with polycystic ovary syndrome. Obstet Gynaecol. 2004;6:145–51.
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–62.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89: 2745–9.
Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006;80:105–14.
Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med. 2013;58(3–4):107–14.
Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A.MANAGEMENTOF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of Bilateral Adrenal Incidentalomas. Eur J Endocrinol. 2018;179(2):R57–R67.
Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF,Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J ClinEndocrinol Metab. 2003;88:2562–8.
Coviello AD, Kaplan B, LakshmanKM, Chen T, SinghAB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93:914–9.
Fauser B, Tarlatzis B, Rebar R, Legro R, Balen A, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14–24.
Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. HumReprod Update. 2008;14:367–78.
GeffnerME,GoldeDW. Selective insulin action on skin, ovary, and heart in insulin-resistant states. Diabetes Care. 1988;11:500–5.
Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res. 2014;40:1353–60.
Goyal M, Dawood AS. Debates regarding lean patients with polycystic ovary syndrome: a narrative review. J Hum Reprod Sci. 2017; 10:154–61.
Han Y, Kim HS, Lee H-J, Oh J-Y, Sung Y-A. Metabolic effects of polycystic ovary syndrome in adolescents. Ann Pediatr Endocrinol Metab. 2015;20:136–42.
Hsueh AJW, Kawamura K, Cheng Y, Fauser BCJM. Intraovarian control of early Folliculogenesis. Endocr Rev. 2015;36:1–24.
Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, et al. An international consortium update: pathophysiology, diagnosis,and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88:371–95.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–51.
Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, AlvaresM. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod BioMed Online. 2005;10:100–4.
Lebbe M, Woodruff TK. Involvement of androgens in ovarian health and disease. Mol Hum Reprod. 2013;19:828–37.
Mihailidis J, Dermesropian R, Taxel P, Luthra P, Grant-Kels JM. Endocrine evaluation of hirsutism. Int J Womens Dermatol. 2017;3(1 Suppl):S6–S10.
Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481.
Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075–9.
Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. Am J Obstet Gynecol. 2012;207:377-e1-8.
Pappachan JM, Hariman C, Edavalath M, Waldron J, Hanna FW. Cushing's syndrome: a practical approach to diagnosis and differential diagnoses. J Clin Pathol. 2017;70:350–9.
Popova P, Ivanova L, Karonova T, Grineva E. Ovulation induction by metformin in lean and obese women with polycystic ovary syndrome. Endocr Abstr 2011;26(P90).
Pugeat M, Plotton I, de la Perrière AB, Raverot G, Déchaud H,Raverot V. MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. Eur J Endocrinol. 2018;178:R141–54.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
Saenger P. Metabolic consequences of growth hormone treatment in paediatric practice. Horm Res. 2000;53(Suppl. 1):60–9.
Simmonds MJ, Milne N, Ong K, Brotherton E, McNamee AP, Horobin J, et al. Physical properties of blood are altered in young and lean women with polycystic ovary syndrome. PLoS One.2016;11:e0167290.
Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.
SongDK, Hong YS, SungY-A, Lee H. Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance. PLoS One. 2017;12:e0178120.
Sprung VS, AtkinsonG, Cuthbertson DJ, Pugh CJA,Aziz N, Green DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol. 2013; 78:438–46.
